Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.
Efgartigimod may induce a partial response in refractory ITP, which can be enhanced by TPO-RAs, leading to sustained remission.
Where it sits
this study against the rest of the efpeglenatide corpusSummary and findings
This case study describes a patient with refractory immune thrombocytopenia (ITP) who experienced a partial response to efgartigimod, which was enhanced by the addition of eltrombopag. The patient maintained a durable remission for 24 weeks after discontinuation of efgartigimod. The study also notes changes in immature platelet indices during treatment.
Abstract
Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, represents a novel therapeutic approach for refractory immune thrombocytopenia (ITP). However, its clinical positioning and durability of response in real-world settings remain unclear. We describe a case of refractory ITP in which efgartigimod induced a partial response that was enhanced by the subsequent addition of a thrombopoietin receptor agonist (TPO-RA), resulting in durable remission after efgartigimod discontinuation. Subsequent hematologic workup revealed that platelet recovery was accompanied by a reciprocal shift in immature platelet indices, with immature platelet fraction percentage decreasing and absolute immature platelet fraction increasing. Although there is a paucity of literature on immature platelet indices during ITP treatment, these parameters may serve as useful biomarkers for monitoring therapeutic response. Notably, efgartigimod was discontinued after 22 weeks, with sustained response maintained for an additional 24 weeks on TPO-RA monotherapy. This treatment course highlights the potential of FcRn inhibition to induce durable immunomodulatory effects and demonstrates synergistic benefits with TPO-RAs-insights that extend beyond the scope of conventional clinical trial protocols.
Background
This paper addresses the clinical question of how efgartigimod, an FcRn antagonist, can affect treatment outcomes in refractory immune thrombocytopenia (ITP). Previous studies have suggested potential benefits of FcRn inhibition, but the durability of response in real-world settings remains unclear. This case study aims to provide insights into the therapeutic positioning of efgartigimod and its interaction with thrombopoietin receptor agonists (TPO-RAs).
Methods
This is a case report detailing the treatment of a single patient with refractory ITP. Efgartigimod was administered for 22 weeks, followed by eltrombopag. The primary outcomes measured were platelet response and immature platelet indices, with no specific n or statistical methods reported.
Results
Efgartigimod induced a partial response in the patient, which was enhanced by the addition of a TPO-RA. The immature platelet fraction percentage decreased while the absolute immature platelet fraction increased. The patient maintained a sustained response for 24 weeks after discontinuation of efgartigimod.
Interpretation
The findings suggest that efgartigimod may have a role in inducing durable responses in ITP, particularly when combined with TPO-RAs. However, the lack of a control group and the single-case nature of the report limit the ability to draw broader conclusions. The effect sizes observed may not be clinically meaningful without comparative data.
Key findings
- Efgartigimod was administered for 22 weeks.
- Sustained response maintained for an additional 24 weeks on TPO-RA monotherapy.
- Immature platelet fraction percentage decreased.
- Absolute immature platelet fraction increased.
Limitations
- Single case report with no control group.
- No statistical analysis provided.
- Limited generalizability of findings.
- Short follow-up period after treatment discontinuation.